The Federal Trade Commission has told pharmacy benefit managers to disregard what the FTC calls its outdated guidelines, a move that pharmaceutical lawyers and professors said indicates the agency will take a stricter regulatory stance with PBMs.

“It’s clear that PBMs are in the crosshairs at the moment” between the FTC and congressional efforts to ensure the industry is held accountable, said Lee Rosebush, a Baker & Hostetler partner who heads the firm’s pharmacy team. “The FTC is diving head first” into the PBM space, he added. 

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]